JCJan J. Cornelis

Jan J. Cornelis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan J. Cornelis has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Jean Rommelaere

    Program Infection, Inflammation and Cancer, Clinical Cooperation Unit Virotherapy (F230), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

    3 shared publications
  • Alexandra Y. Stroh-Dege

    Applied Tumor Virology Program, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    2 shared publications
  • Christiane Dinsart

    Applied Tumor Virology Program, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    2 shared publications
  • Christiane Dinsart

    Division of Tumor Virology, Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, Heidelberg 69120, Germany

    2 shared publications
  • Jean Rommelaere

    Applied Tumor Virology Program, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    2 shared publications
  • Susanne I. Lang

    Applied Tumor Virology Program, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    2 shared publications

Latest Publications

  • Parvovirus

    by Jean Rommelaere, José M. Almendral del Río, Jan Cornelis, Jürg P. F. Nüesch

  • Humoral immune responses against minute virus of mice vectors

    by Susanne I. Lang, Nathalia A. Giese, Jean Rommelaere, Christiane Dinsart, Jan J. Cornelis

    Background Owing to their oncolytic properties, autonomous rodent parvoviruses and derived vectors constitute potential anti-tumor agents. Methods Humoral immune responses to minute virus of mice (MVMp) were characterized. In particular, the generation of neutralizing antibodies on subsequent therapeutic virus applications was evaluated in a mouse melanoma model. Mice bearing subcutaneous melanomas were injected intratumorally with virus and re-injected 10 days later in a second tumor on the other flank. Four days after the first or second injection, the tumors and lymph nodes were analyzed by RT-PCR for gene expression. Results Injection of MVMp in tumor-bearing B6 mice resulted in viral gene expression in tumors and draining lymph nodes. A repeated virus administration did not lead to detectable viral transcription if it was preceded by a virus infection 10 days earlier. This protection correlated with the induction of virus-neutralizing antibodies following the first virus application. The restrictions on viral gene expression after a consecutive MVMp injection could be alleviated in subsequent applications by the use of viruses consisting of MVMp genomes packaged into capsids of a related parvovirus. Neutralizing antibody induction was irrespective of the route of administration and of the presence of a tumor and persisted at significant levels at least up to 26 weeks after the viral infection. MVMp infection of B6 mice stimulated the generation of IgM and IgG anti-viral antibodies, the latter mainly of the T-helper (Th) 1-dependent IgG2, and the T-cell-independent IgG3 subclasses. Conclusions Neutralizing antibodies impede the effectiveness of a subsequent virus administration, but can be overcome by pseudotyping. Copyright © 2006 John Wiley & Sons, Ltd.


  • The Infectivity and Lytic Activity of Minute Virus of Mice Wild-Type and Derived Vector Particles Are Strikingly Different

    by Susanne I. Lang, Stephanie Boelz, Alexandra Y. Stroh-Dege, Jean Rommelaere, Christiane Dinsart, Jan J. Cornelis

    Gene therapy vectors have been developed from autonomous rodent parvoviruses that carry a therapeutic gene or a marker gene in place of the genes encoding the capsid proteins. These vectors are currently evaluated in preclinical experiments. The infectivity of the vector particles deriving from the fibroblastic strain of minute virus of mice (MVMp) (produced by transfection in human cells) was found to be far less (approximately 50-fold-less) infectious than that of wild-type virus particles routinely produced by infection of A9 mouse fibroblasts. Similarly, wild-type MVMp produced by transfection also had a low infectivity in mouse cells, indicating that the method and producer cells influence the infectivity of the virus produced. Interestingly, producer cells made as many full vector particles as wild-type particles, arguing against deficient packaging being responsible for the low infectivity of viruses recovered from transfected cells. The hurdle to infection with full particles produced through transfection was found to take place at an early step following entry and limiting viral DNA replication and gene expression. Infections with transfection or infection-derived virus stocks normalized for their replication ability yielded similar monomer and dimer DNA amplification and gene expression levels. Surprisingly, at equivalent replication units, the capacity of parvovirus vectors to kill tumor cells was lower than that of the parental wild-type virus produced under the same transfection conditions, suggesting that beside the viral nonstructural proteins, the capsid proteins, assembled capsids, or the corresponding coding region contribute to the lytic activity of these viruses.


  • Cancer Gene Therapy through Autonomous Parvovirus - Mediated Gene Transfer

    by Jan J. Cornelis, Susanne I. Lang, Alexandra Y. Stroh-Dege, Ginette Balboni, Christiane Dinsart, Jean Rommelaere

    Parvoviruses are small nuclear replicating DNA viruses. The rodent parvoviruses are usually weakly pathogenic in adult animals, bind to cell surface receptors which are fairly ubiquitously expressed on cells, and do not appear to integrate into host chromosomes during either lytic or persistent infection. The closely related rodent parvoviruses MVM, H-1 and LuIII efficiently infect human cell lines. Most interesting, malignant transformation of human and rodent cells was often found to correlate with a greater susceptibility to parvovirus-induced killing (oncolysis) and with an increase in the cellular capacity for amplifying and / or expressing the incoming parvoviral DNA. These and other interesting properties make these autonomous rodent parvoviruses and recombinant derivatives promising candidate antitumor vectors. Capsid replacement vectors have been produced from MVM or H-1 virus that carry transgenes encoding either therapeutic products (cytokines / chemokines, Apoptin, herpes simplex virus thymidine kinase) or marker proteins (green fluorescent protein, chloramphenicolacetyl transferase, luciferase). This review describes the current state of the art regarding the potential application of wild-type parvoviruses and derived vectors for the treatment of cancer. In particular, recent successes with the development of replication-competent virusfree vector stocks are discussed and results from pre-clinical studies using recombinant parvoviruses transducing various cytokines / chemokines are presented.


  • Vectors based on autonomous parvoviruses: novel tools to treat cancer?

    by Jan J. Cornelis, Nathalie Salomé, Christiane Dinsart, Jean Rommelaere

    Autonomous parvoviruses are small nuclear‐replicating DNA viruses. The rodent parvoviruses usually are non‐ or weakly pathogenic in adult animals, bind to surface receptors which are expressed on most cells, and do not appear to integrate into host chromosomes during either lytic or persistent infections. Interestingly, malignant transformation of the target cells was often found to correlate with an increase in their capacity for amplifying and/or expressing the incoming parvoviral DNA, and is associated with oncolysis, i.e., the selective killing of the infected tumor cells. Moreover, the closely related parvoviruses MVM, H‐1 and LuIII efficiently infect human cell lines. This finding makes these parvoviruses promising candidate vectors for therapies that require transient expression of a transduced gene. In particular, parvoviruses may be suitable to target and kill tumor cells and simultaneously deliver appropriate transgenes, e.g., genes coding for immuno‐stimulatory factors. Pilot experiments performed in animals to assess whether parvovirus‐based vectors carrying the interleukin 2 (IL‐2) cytokine gene have reinforced anti‐cancer capacity showed that these recombinant viruses suppressed tumor formation more efficiently than viruses devoid of a transgene. Strong anti‐cancer effects of recombinant parvoviruses expressing interferon γ‐inducible protein 10 (IP‐10) and monocyte chemotactic protein 3 (MCP‐3) were also observed against established hemangiosarcomas and melanomas in immuno‐competent mice, respectively. Altogether, these data illustrate the enormous potential of recombinant autonomous parvoviruses as anti‐tumor agents and give hope of using them against human cancer. Copyright © 2004 John Wiley & Sons, Ltd.